Topotecan + ara-C and fludarabine + ara-C regimens in acute myeloid leukemia (AML).
| A. Regimen Schedule . | |||
|---|---|---|---|
| 1. | IA ara-C | IDA 1.5 g/m2/CI/D × 3-4 | 12 mg/m2/D × 3 |
| 2. | FAIA ara-C | fludarabine 2 g/m2 over 4 h/D × 5 | 30 mg/m2/D × 5 |
| 3. | TA ara-C | Topotecan 1-2 g/m2 over 2-4 h/D × 5 | 1.25 mg/m2 CI/D × 5 |
| A. Regimen Schedule . | |||
|---|---|---|---|
| 1. | IA ara-C | IDA 1.5 g/m2/CI/D × 3-4 | 12 mg/m2/D × 3 |
| 2. | FAIA ara-C | fludarabine 2 g/m2 over 4 h/D × 5 | 30 mg/m2/D × 5 |
| 3. | TA ara-C | Topotecan 1-2 g/m2 over 2-4 h/D × 5 | 1.25 mg/m2 CI/D × 5 |
| B. Results . | . | . | . | . |
|---|---|---|---|---|
| Regimen . | No. . | % CR . | EFS . | Median Survival (wks) . |
| Abbreviations: IDA indicates idarubicin; CI, confidence interval; CR, complete remission; EFS, event-free survival. | ||||
| IA | 322 | 77 | 63 | 77 |
| FA | 600 | 55 | 40 | 30 |
| TA | 357 | 59 | 36 | 41 |
| B. Results . | . | . | . | . |
|---|---|---|---|---|
| Regimen . | No. . | % CR . | EFS . | Median Survival (wks) . |
| Abbreviations: IDA indicates idarubicin; CI, confidence interval; CR, complete remission; EFS, event-free survival. | ||||
| IA | 322 | 77 | 63 | 77 |
| FA | 600 | 55 | 40 | 30 |
| TA | 357 | 59 | 36 | 41 |